ArticleCurrent opinion in physiology2025
Caveolin in extracellular vesicles: orchestrating interorgan communication in diabetes-associated cardiovascular disease
Article in Current opinion in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Small extracellular vesicles (sEVs) have been recognized as critical mediators of intercellular communication, impacting processes such as inflammation, tissue repair, and cardiovascular disease progression. Conventionally, research has focused on the general role of sEVs in mediating the signals among cell-cell communication without specifically considering the underlying molecular regulators. However, recent insights highlight the emerging importance of Caveolin, a protein integral to the formation of caveolae, in the regulation of EV biogenesis and release, particularly exosomes. This review underscores the novel role of Caveolin in sEV in shaping interorgan communication via sEV-mediated signaling and how it alters the cardiovascular disease development via modulating multiple pathways. These causes of sEVs transport crucial signaling molecules, including small RNAs and proteins, capable of modulating disease progression positively or negatively. Furthermore, we emphasize novel developments regarding Caveolin-1's influence on diabetes-related cardiovascular pathologies and metabolic disturbances, specifically insulin secretion, insulin signaling, insulin resistance, oxidative stress, and diabetes-associated complications. By bridging traditional views with recent advancements, this review seeks to provide a comprehensive understanding of Caveolin-1's potential as a therapeutic target in cardiovascular and metabolic disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.